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http://dx.doi.org/10.1016/j.jmii.2013Anti-tumor necrosis factor-a (TNF-a) biological agents, including soluble TNF-a receptors and
anti-TNF-a monoclonal antibodies, bring new hope for treating rheumatic diseases such as
rheumatoid arthritis, but also increase the risk of infection, especially tuberculosis (TB) infec-
tion. Recent findings have shown that the physiological TNF-mediated signaling was somehow
impaired by TNF antagonists, leading to the exacerbation of chronic infection associated with
aberrant granuloma formation and maintenance. Although both receptor and antibody agents
appear to pose an equally high risk in causing development of new TB infections, monoclonal
anti-TNF-a antibody seems more inclined to reactivate latent TB infection. This review is
focused on the underlying mechanisms that cause the TB risk in the anti-TNF-a therapy and
also the strategies to deal with it, with the aim of reducing the TB incidence during anti-
TNF-a biological therapies.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The development of anti-tumor necrosis factor-a (TNF-a)
therapy brings new hope for treating rheumatic diseases in
which TNF-a plays a crucial role, including rheumatoidt of Rheumatology and Clin-
a Hospital of Center South
dle Road, Changsha, Hunan
.com (F. Li).
an Society of Microbiology. Publ
.03.005arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis
(PsA), and other inflammatory arthritis. Anti-TNF-a therapy
not only relieves symptoms, but also reduces bone erosions
to a minimal degree, which may lead to a better prognosis.
However, TNF-a is also a key cytokine in host defense
against intracellular infection, such as mycobacterium
tuberculosis (MTb) infection.1,2 In daily practice it is
confirmed that anti-TNF-a therapy is also associated with
increased susceptibility to infections, especially tubercu-
losis (TB).3 It is also found that anti-TNF-a monoclonal an-
tibodies appear to pose a higher risk in TB infection thanished by Elsevier Taiwan LLC. All rights reserved.
Risk of TB infection in anti-TNF-a biological therapy 269TNF-a receptors.4 In this review we focus on the underlying
mechanisms that cause the differences in MTb risks among
different kinds of anti-TNF-a agents, with the aim of
reducing the MTb incidence to a minimal degree during
anti-TNF-a biological therapies.
TB infection
TB is caused by a bacterium called Mycobacterium tuber-
culosis (M. tuberculosis). The bacterium usually attacks the
lungs, but it can also attack other parts of the body such as
the kidney, spine, brain, intestines and so forth. If not
treated properly, TB infection can be fatal. Not all patients
infected with M. tuberculosis become symptomatic. Two
TB-related conditions exist: active TB (ATB) disease and
latent TB infection (LTBI).
It is noteworthy that LTBI refers to a TB infection status in
which the patient is infected with M. tuberculosis but re-
mains asymptomatic. Themain adverse consequence of LTBI
is that approximately 5e10% of these patientswill eventually
goon todevelopATBat a later stageof their life. Thegreatest
risk of progression to ATB occurs in the first 2 years after
infection.5 However, the risk may be higher if the patient is
receiving concurrent immunosuppressive therapy and it is
even worse if a patient suffers a disease that disturbs the
immune system or is complicated with malnutrition. More-
over, old age is also associated with TB infection, since the
immune system weakens with age.6,7
Factors increasing the risk of TB infection
There aremany factors that increase the risk of TB infection.
Among these factors, the immunosuppressive conditions top
the list. The risk of developing TB is about 100-fold increased
in the HIV-infected population.8e10 Solid organ transplant
recipients have an elevated risk of TB infection because of
immunosuppressive therapy.11,12 In an investigation in Spain,
the incidence of TB in recipients was 26.6 times higher than
that in the general population and the highest TB incidence
was observed among lung transplant recipients, with a rela-
tive risk of 73.3.12 In patients receiving anti-TNF-a treat-
ment, the relative risk of TB infection varies from 1.5 to
17.13,14 The risk of TB infection is higher with anti-TNF-a
monoclonal antibody therapy than with soluble TNF-a re-
ceptor therapy.4,15 In a study in the US, the risk of developing
TB attributed to infliximab was more than twofold that of
etanercept.16 Tissue malignancy also has an influence on the
risk for TB infection. In patients with hematological malig-
nancies including leukemia and lymphoma, the relative risk
of developing TB reaches 16.17 Additionally, other condi-
tions, such as diabetes mellitus, smokers, alcoholics, also
have two- to threefold increased risks of developing TB.18e20
Risks of TB infection by different TNF-a
antagonists
With increasing biologic agents becoming available for
clinical use, there are more and more concerns about the
increased rates of infections secondary to the disturbance
of physiological cytokine-mediated signalings by theseagents.21 It had been reported that an increased risk of TB
infection was associated with biological therapies,
including TNF-a antagonists (monoclonal anti-TNF-a anti-
body: adalimumab, infliximab, certolizumab pegol and
soluble TNF-a receptor: etanercept),3,22 anakinra (IL-1 re-
ceptor antagonist),23 abatacept (CTLA-4 Ig),24 rituximab
(monoclonal anti-CD20 antibody),25 efalizumab (mono-
clonal anti-CD11a antibody),26 daclizumab (monoclonal
antibody to the interleukin 2 receptor-CD25)27and so on,
among which TNF-a antagonists seem extremely prominent
for increasing the risks of TB infection.
In a retrospective cohort of 112,300 Canadian RA pa-
tients from 1998 to 2003, the rate of TB was investigated to
determine whether different disease-modifying antirheu-
matic drugs (DMARDs) were associated with the risk of TB.
The researcher found that the median time from the first
prescription with infliximab or etanercept to the presen-
tation of TB was 17 and 79 weeks, respectively.14 Another
research reviewed 90 RA patients treated with infliximab
and 103 patients treated with etanercept, by analyzing the
data of the Korean National Tuberculosis Association (KNTA)
from 2001 to 2005; in the infliximab-treated RA group, two
cases of TB developed, while there was no case of TB re-
ported in the etanercept-treated RA group.15
In 2008, Wallis28 reported 248 cases of infliximab-
associated and 39 cases of etanercept-associated TB in-
fections, which were recorded from January 1998 to March
2003 in the Adverse Events Reporting System (AERS) data-
base of the Food and Drug Administration (FDA). According
to the report, among 197,000 infliximab-treated and
113,000 etanercept-treated patients, the TB incidence rate
was 54 per 100,000 and 28 per 100,000, respectively. Monte
Carlo simulation revealed that the median time of TB onset
after starting etanercept therapy is three to five times
longer than infliximab (12e21weeks). A median rate of
reactivation of LTBI by infliximab treatment was 12.1 times
higher than the etanercept treatment (p < 0.001). In
contrast, both TNF-a antagonists appeared to pose a high
risk of progression of new TB infection.
A French prospective research4 reported that the annual
adjusted incidence rate of TB was 9.3 (range 0.0e9.4) per
100,000 for patients receiving etanercept, 187.5 (range
0.1e374.8) per 100,000 for infliximab, and 215.0 (range
0.0e521.7) per 100,000 for adalimumab, compared with 8.7
per 100,000 for the general French population. The stan-
dardized incidence ratio (SIR) was 1.8 (95% CI Z 0.7e4.3;
p Z 0.20) for etanercept, 18.6 (95% CI Z 13.4e25.8;
p < 0.0001) for infliximab, and 29.3 (95% CI Z 20.3e42.4;
p < 0.0001) for adalimumab. British research29 published in
2010 showed that the incidence rate of TB was highest for
adalimumab (144 events/100,000 person-years), followed by
infliximab (136/100,000 person-years) and then etanercept
(39/100,000 person-years). Compared with etanercept, the
adjusted incidence rate ratios (IRRs) and 95% CI for adalimu-
mab and infliximab were 4.2 (1.4e12.4) and 3.1 (1.0e9.5),
respectively. The median time from the initial TNF-a antago-
nist use to TB diagnosis was 13.4 months for cases exposed to
etanercept, 5.5 months for infliximab and 18.5 months for
adalimumab.
From the data above, it can be concluded that the inci-
dence of TB induced by various TNF-a antagonists are
different; monoclonal anti-TNF-a antibodies such as
270 X. Xie et al.infliximab or adalimumab poses a higher risk of TB incidence
than soluble TNF-a receptor, etanercept. Themedian time of
TB onset after receiving monoclonal antibody therapy was
shorter than that of soluble receptor. Anti-TNF-a antibody
seems more inclined to reactivate a latent TB infection,
although both TNF-a antagonists appear to pose an equally
high risk in causing the development of new TB infection.30Mechanisms of TB infection in different TNF-a
antagonists
Themechanism that underlies increased TB infection in TNF-
a antagonist therapies has aroused researchers’ interests.
TNF-a is a cytokine that plays a central role in establishing
and maintaining the inflammatory response against in-
fections.1,2,31,32 TNF-a has soluble and transmembrane
forms, both of which are biologically active and are pro-
duced by a wide variety of cells, including macrophages,
natural killer cells, granulocytes, fibroblasts, and T cells.
Both forms of TNF-a interact with two distinct types of re-
ceptors, TNF receptor 1 (TNFR1) and TNFR2. Either or both
forms of TNF-a are found in practically all cells of the human
body, except red blood cells. TNF-a blockade will result in
the interruption of TNFR-mediated functions, which com-
prises cell activation and proliferation, production of cyto-
kines and chemokines, and the formation and maintenance
of granulomas.33 In the host immune response, the myco-
bacteria arrives in the alveoli and is engulfed by alveolar
macrophages. TNF-a is then released with an autocrine
style, an action which further enhances the release of other
cytokines and chemokines to attract and activate CD4þ,
CD8þ and g/d lymphocytes. These lymphocytes strengthen
T-cell adhesion and antigen presentation, which results in
the proliferation and recruitment of more T and B cells.
These activated cells also release interferon-g (IFN-g),
which accelerates antigen presentation and induces intra-
cellular killing of bacilli and macrophage apoptosis. Finally,
granuloma formation and infection occurs; however, if the
patients have no symptoms, but have mycobacteria within
the body, it is termed LTBI. Under such circumstances, MTb-
specific central memory T cells (CCR7þCD27þ) and effector
memory cells (CCR7eCD27e) will permanently exist in the
body. Thus, anti-TNF-a therapy disturbs the physiological
TNF-a mediated immunoinflammatory responses and may
cause TB reactivation or dissemination.33e35
Plessner et al36 investigated the effects of anti-TNF-a
antibody (MP6-XT22) and soluble TNFR fusion molecule
(mTNFR2-Fc) in the murine TB model. Both MP6-XT22 and
mTNFR2-Fc resulted in rapid morbidity in acute infection.
During chronic infection, mTNFR2-Fc related infection could
be controlled, whereas TB infection secondary to MP6-XT22
caused death within 1 month. Histological proof showed that
the lung sections of mTNFR2-Fc-treated mice had lower bac-
terial burden than those of MP6-XT22-treated mice. Also,
granuloma formation and maintenance were better in the
mTNFR2-Fc group than the MP6-XT22 group, and this effect
wasmore significantwith the progression of time and increase
in drug dose. During acute infection, flow cytometry revealed
increased C3 deposition on CD4þ T cells in the lungs of mice
treated with MP6-XT22 compared with those of mTNFR2-Fc-
treatedmice; therewere significantly fewer CD4þ Tcells, andnot macrophages, in the lungs of MP6-XT22-treated mice
compared with those of mTNFR2-Fc-treated mice, during
primary infection but not in chronic infection. Drug fluores-
cent staining analysis showed a higher concentration of MP6-
XT22 in the lungs. These findings were a good start to clarify
the differences in the mechanism of inducing and exacer-
bating TB infection by different anti-TNF-a agents. In other
research,37 C57BL/6 mice with chronic TB infection were
treated with the TNF-neutralizing antibody MP6-XT22 or
normal rat IgG. The results showed that the lymphoid aggre-
gates were well maintained in the infected lungs of rats in the
IgG-treated group 9 days after treatment; in contrast, the
dissolution of lymphoid nodules in the MP6-XT22-treated
group became obvious and continued to be apparent at 21
days. Further immunohistochemical studies showed that the
dissociationofB-cell-macrophageunits in the infected lungsof
the MP6-XT22 treated group was particularly conspicuous,
with a marked decrease in the expression of cells with CD19,
which is the early differentiation antigen of the B cell. Lin
et al38 undertook an investigation on a cynomolgus macaque
model. Macaques were classified as having active or latent
disease 6e8 months after TB infection. Then, macaques with
acute infection were randomized to receive either adalimu-
mab or no treatment, while macaques with latent infection
were randomized to receive treatment with a TNF-
neutralizing agent, either p55-TNFRI or adalimumab, or with
saline. The results showed that neutralization of TNF in
latently infected macaques caused reactivation in a majority
ofanimals, asdeterminedbygrosspathologicexaminationand
bacterial burden. A spectrum of dissemination was noted,
including extrapulmonary disease. However, macaques that
developed primary and reactivated TB after TNF neutraliza-
tion had a similar granuloma structure andcomposition to that
of control macaques with active disease. TNF neutralization
was associated with increased levels of interleukin-12 and
chemokinereceptorexpression,decreased levelsofCCL4, and
reducedmycobacteria-induced IFN-g production in blood, but
not in theaffectedmediastinal lymphnodes. Interestingly, the
first sign of reactivation often occurred in thoracic lymph
nodes. In an in vitro study,39 Saliu et al found that infliximab
and adalimumab significantly inhibited T cell activation and
reduced theproportionofTB-responsiveCD4þ cells by70%and
50%, respectively, while etanercept produced no significant
effect. Infliximab and adalimumab obviously suppressed IFN-g
produced by TB-responsive CD4þ cells. However, IL-10 pro-
duction was equally suppressed by all three anti-TNF drugs.
Wallis35 concluded that the differences in risks of TB
infection among TNF antagonists are caused by their
different structures and functions, including pharmacoki-
netics and dosing, soluble TNF binding kinetics and stoi-
chiometry, the affinities of TNF antagonists for
transmembrane TNF, cytotoxicity, apoptosis and T-cell
activation, and cytokine expression.
Diagnosis of latent TB infection before anti-
TNF-a therapy
Tuberculin skin test
LTBI is diagnosed in patients who are free from symptoms of
ATB disease, but have a positive tuberculin skin test (TST).
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world. A number of countries have generated national
guidelines that deal with LTBI before anti-TNF drugs
therapy.7,40,41
In China, where TB prevalence is very high, the criterion
of LTBI diagnosis may be less valuable and the guiding
principle for LTBI treatment may not be as strict as in the
US or European countries. Considering this, the risk of TB
infection induced by biological drugs becomes more unop-
timistic. Therefore, the Chinese Rheumatology Association
suggested a TST induration diameter  10 mm as the
threshold of applying biological agents in RA and AS.42,43
The specific standards are as follows: (1) the induration
diameter  10 mm, and no evidence of TB infection, bi-
ologics are available; (2) the induration diameter > 10 mm
and  15 mm, without evidence of TB infection, the use of
biologics depends on the patient disease condition. If
necessary, it is suggested to be applied simultaneously with
anti-TB treatment; (3) the induration diameter  15 mm or
<15 mm with blister or necrosis, biologics are not recom-
mended unless the TB is controlled after anti-TB treat-
ment. However, TST is easily influenced by many factors,
such as Bacille Calmette Gue´rin (BCG), which is widely used
in young Chinese populations.42,43 Diagnosis of LTBI is
necessary, but still challenging in daily practice (Fig. 1).
Interferon-gamma release assay (IGRA)
IGRA is established as an alternative to the TST in TB
infection diagnosis, especially when it comes to the diag-
nosis of LTBI, in which IGRA plays an important and unique
role. The development of IGRA should be attributed to the
progress of molecular biology and immunology.44 In 1999,
Behr et al45 performed comparative hybridization experi-
ments on a DNA microarray, to better understand the dif-
ferences among M. tuberculosis, Mycobacterium bovis, and
the various BCG daughter strains. Eleven regions (encom-
passing 91 open reading frames) of H37Rv deleted from BCG
vaccines and M. bovis were confirmed by sequencing. Five
additional regions representing 38 open reading frames
were present in M. bovis, but absent from BCG strains. The
differences between MTB and BCG were determined by
these 16 regions denoted RD1eRD16. Of particular impor-
tance was that the region of deletion-1 (RD-1) was
completely deleted from all BCG strains and most envi-
ronmental mycobacteria. Therefore, detection of RD-1-
encoded antigen-specific T-cells response revealed
whether the suspected person was infected with MTB or
not. Early secreted antigenic target 6-kDa protein (ESAT-6)
and culture filtrate protein 10 (CFP-10), which were two of
the RD-1-encoded proteins, can theoretically evoke robust
CD4þ and CD8þ T-cell responses. When the body was re-
stimulated by a mycobacteria-specific antigen, memory
cells which had been immunized primarily would be re-
activated rapidly and release IFN-g. By detecting IFN-g
secretion, it was possible to find out if the body had been
infected by TB without interference by previous BCG
vaccination or atypical mycobacterial infection. It can be
inferred from the abovementioned mechanisms that IGRA is
particularly important in the diagnosis of LTBI, since it is
asymptomatic. Unfortunately, the current diagnostic kits
utilizing production of IFN-g in response to TB antigens, areunable to distinguish between LTBI and ATB disease. Efforts
had been made to distinguish between LTBI and ATB dis-
ease, by assessing multiple cytokines such as TNF-a, IL-12
and IL-17, which is helpful to confirm the diagnosis of ATB
disease in a TB-endemic population.46
There are two different sets of IGRA test, including T-
SPOT.TB and Quanti FERON-TB Gold (or Quanti FERON-TB
Gold in Tube). The T-SPOT.TB test is based on the high
sensitive enzyme-linked immunospot assay that enumer-
ates the number of T-cells releasing IFN-g in the peripheral
blood, which responds to the stimulation by MTb-specific
antigens. The method of Quanti FERON-TB is based on the
whole-blood ELISA test of IFN-g released from T-cells, in
response to the stimulation by MTb-specific antigens.
Because of different local commercial permissions, head-
to-head comparisons between these two assays for LTBI are
rare and most of them were performed in Japan. A study
speculated that T-SPOT.TB might reduce the frequency of
indeterminate results of Quanti FERON-TB Gold.47 However,
another study noted that LTBI in younger patients may be
better diagnosed by Quanti FERON-TB Gold or Quanti
FERON-TB Gold in Tube, while in middle-aged and elderly
patients, T-SPOT.TB may be more suitable to exclude LTBI,
although the validity of two methods in the exclusion of
LTBI are similar and not fully enough to diagnose LTBI
separately.48
Comparison and interaction between TST and IGRA
It is newly accepted that the specificity of IGRA is greatly
improved compared with TST (97% for Quanti FERON-TB
Gold and 92% for T-SPOT.TB vs. only 66% for TST).49,50 It had
been widely accepted that T-SPOT.TB is superior on the
predictability of TB infection in immunosuppressed pa-
tients, and it was not influenced by immunosuppression
status, such as HIV infection.51 The new data showed that
T-SPOT.TB may be more sensitive than the TST in patients
receiving anti-TNF-a therapy.52
Considering that the TST has a low specificity in TB diag-
nosis and its result is always affected by many other factors,
IGRA is regarded as an alternative to TST in the diagnosis of
ATB disease and LTBI in the US.53 However, in Britain, the
guideline recommends the combination of both methods.54
Currently, there is a tendency that IGRA may be used as a
substitute for TST in the diagnosis of LTBI before starting
TNF-a antagonists, especially in countries where TB preva-
lence is intermediate and the BCG vaccination is mandatory
at birth, such as in Korea.55 In China, T-SPOT.TB was
approved by the State Food and Drug Administration in
September 2010. A consensus report of a Chinese infliximab
and etanercept study group also suggested that T-SPOT.TB
should be advised in TST-positive patients before the
administration of TNF-a antagonists.42,43 However, the
phenomenon of poor agreement between TST and IGRA was
found in many studies of different populations and multi-
centered, large-scaled and randomized comparative studies
between the TST test and IGRA are still lacking. A strategy of
simultaneous testing to optimize diagnostic sensitivity is
suggested in the clinical use of biological drugs.
A recently published study56 aimed to figure out the
impact of TST on subsequent IGRA results. TST-mediated
negative positive
no
noyes
noyes
Patient assessment : past history, TB exposure, symptoms and signs, chest X-ray 
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Figure 1. Tuberculosis screening diagram in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients for anti-TNF-a
therapy in our clinic.
272 X. Xie et al.boosting of IGRA responses were evaluated in 26 South Af-
rican volunteers. IGRAs were performed pre-TST, and were
repeated four times on Days 3, 7, 28, and 84 post-TST
administration. The results showed that IGRAs performed
post-TST were obviously elevated since Day 3. The reporter
advised that when using a two-step screening strategy, it is
better to perform an IGRA within 3 days after performing
the TST.
Screening new antigens for diagnosis of TB
Finding new TB antigens specific for MTb is ongoing.
Heparin-binding hemagglutinin (HBHA) became a candi-
date. A study showed that LTBI individuals mount a strong
T-cell response to HBHA, whereas patients with ATB disease
do not, suggesting that HBHA is a good marker for the
immunodiagnosis of LTBI, and that HBHA-specific Th1 re-
sponses may contribute to protective immunity against
ATB.57 An updated report published in Nature also demon-
strates an underappreciated role of type I IFN-ab signaling
in the pathogenesis of TB, which has implications for the
development of a vaccine and therapy.58
Decline in the incidence of LTBI after strengthening
TB control
With increasing concerns in the safety of anti-TNF-a agents,
especially in patients with possible LTBI, there appeared a
decline in the incidence of reactivation of LTBI in the
general population. Several retrospective and observa-
tional studies suggested that treatment of LTBI before or
during anti-TNF-a therapy prevented reactivation effec-
tively.40,41 In a single-center retrospective study,59 before
starting etanercept use, 78/84 patients were fully orpartially treated for LTBI with a mean of 2.5 months (0e12
months); no cases of ATB or newly occurred TB were found,
although they were thought to be at high risk for ATB
because 80% were born in TB-endemic countries. Similar
findings were reported by Carmona et al, who analyzed the
Spanish-based BIOBADASER and EMECAR databases. After
adoption of formal guidelines to treat LTBI before initiating
TNF-a antagonists, 324/384 patients (84%) with a positive
purified protein derivative (PPD) received anti-LTBI ther-
apy, and there was a 78% (p Z 0.008) reduction in TB risk
for RA patients treated with infliximab; the TB risk fell to
the background rate of RA patients not receiving anti-TNF-a
therapy.41 In Japan, of 5000 cases of RA patients treated
with infliximab, 11 TB cases developed in the first 2000
patients, however, after intensified TB screening and pro-
phylactic treatment, only three TB cases developed in the
last 3000 patients who received stricter preventive anti-TB
treatment (22.3% in the last 3000 patients vs. 14.0% in the
first 2000 patients taking prophylactic treatment). 60
However, treatment of LTBI before anti-TNF-a therapy is
not universally effective. A retrospective study61 in Greece
reported that in 613 patients who received anti-TNF-a
therapy from July 2000 to June 2004, 11 cases of ATB
developed. Of the 11 cases, eight cases received infliximab
and three received adalimumab; none received etanercept.
Ten cases of ATB developed in the PPD-positive cohort and
one case of ATB in the PPD-negative cohort, however, seven
of the 11 cases of ATB occurred in patients who had
completed or were undergoing LTBI therapy. The failure to
prevent developing ATB in this Greek cohort may be
attributable to inadequate compliance with recommenda-
tions, inadequate length of therapy, higher threshold for
initiation of LTBI therapy (10-mm induration on PPD), or the
use of infliximab instead of etanercept in a population with
a significant background incidence of TB infection.
Risk of TB infection in anti-TNF-a biological therapy 273ATB or reactivation of LTBI associated with anti-TNF-a
agents should be paid more attention to, for the safety of
biological treatment in rheumatic diseases. Although there
lie many puzzles in the mechanism of TB infection under
these circumstances, it is convincing that with stricter
screening for TB infection, especially LTBI, also combined
with aggressive preventive anti-TB treatment, TB infection
associated with anti-TNF-a agents will be under control.
Based on the available data, we recommended IGRA to be a
routine complementary test with TST before anti-TNF-a
treatment.
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